MedTrace Logo

1% Metformin Gel in the Treatment of Class II Furcation Defects

NCT02580331 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2015-10-20

No results posted yet for this study

Summary

Metformin (MF), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a favourable effect on alveolar bone. The present study aims to explore the efficacy of 1% MF gel as a local drug delivery system in adjunct to scaling and root planing (SRP) for the treatment of Class II furcation defects in comparison with placebo gel.

Conditions

  • Chronic Periodontitis

Interventions

DRUG

SRP and placebo

Placement of placebo gel into classII furcation defects after scaling and root planing

DRUG

SRP and 1% metformin

Placement of 1% metformin gel into classII furcation defects after scaling and root planing

Sponsors & Collaborators

  • Government Dental College and Research Institute, Bangalore

    lead OTHER

Principal Investigators

  • A R Pradeep, MDS · GDCRI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02580331 on ClinicalTrials.gov